Find clinical trials for bipolar disorder. Search for bipolar disorder clinical trials in different cities and states across the United States.
Filter
1
Filter results
Results: 120
FeaturedActive & Responsive
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
for
Bipolar Depression
Location: Dothan AL, Little Rock AR, Anaheim CA, Redlands CA,
Sponsor: Intra-Cellular Therapies, Inc.
Sex: All
Age: 10 - 17
Code: NCT06372964
Phase3, Recruiting
Active & ResponsiveNew
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
for
Mania, Bipolar Disorder
Location: Bentonville AR, Little Rock AR, Miami Springs FL,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18 - 65
Code: NCT07140913
Phase3, Recruiting
Active & Responsive
Healthy Lifestyles in Bipolar Disorder: Bay Area Study
for
Bipolar Disorder, Time Restricted Eating
Location: Berkeley CA
Sponsor: University of California, Berkeley
Sex: All
Age: 18 - 65
Code: NCT06555406
Recruiting
Active & Responsive
Cannabidiol for Bipolar Depression (CBD-BD)
for
Bipolar Disorder
Location: Vancouver, Hamilton, Kingston
Sponsor: University of British Columbia
Sex: All
Age: 19 - 70
Code: NCT05867849
Phase3, Recruiting
Active & Responsive
Early Intervention for Youth at High Risk for Bipolar Disorder
for
Bipolar Disorder
Location: Pittsburgh PA
Sponsor: University of Pittsburgh
Sex: All
Age: 12 - 18
Code: NCT04815239
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder
for
Bipolar Disorder
Location: Belmont MA
Sponsor: Mclean Hospital
Sex: All
Age: 18 - 65
Code: NCT05457465
Phase2, Recruiting
Active & Responsive
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor